Oncology
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
AI Wants to Choose Pancreatic Chemo
China Just Put a Bispecific ADC Into Esophageal Cancer
A Breast-Cancer Warning Is Hiding in Aggregated Data
Liver Cancer Is Moving Beyond TACE Alone
ctDNA Is Becoming the New Argument Over Chemotherapy
The Most Powerful Oncology Tool This Week Was a Check-In
Myeloma Patients May Not Need Treatment Forever
Tissue-Agnostic Medicine Has a New Proof Point
Lung Cancer May Be Entering the Chemo-Replacement Fight
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases